C.R. Bard (NYSE: BCR) and LivaNova PLC (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Risk and Volatility
C.R. Bard has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, LivaNova PLC has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Institutional & Insider Ownership
79.3% of C.R. Bard shares are owned by institutional investors. Comparatively, 82.4% of LivaNova PLC shares are owned by institutional investors. 0.8% of C.R. Bard shares are owned by insiders. Comparatively, 0.3% of LivaNova PLC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. LivaNova PLC does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. C.R. Bard has raised its dividend for 45 consecutive years.
This is a breakdown of recent ratings and price targets for C.R. Bard and LivaNova PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
C.R. Bard currently has a consensus price target of $276.38, suggesting a potential downside of 14.63%. LivaNova PLC has a consensus price target of $65.00, suggesting a potential downside of 0.84%. Given LivaNova PLC’s stronger consensus rating and higher probable upside, analysts clearly believe LivaNova PLC is more favorable than C.R. Bard.
This table compares C.R. Bard and LivaNova PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares C.R. Bard and LivaNova PLC’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|C.R. Bard||$3.83 billion||6.14||$1.18 billion||$7.61||42.54|
|LivaNova PLC||$1.21 billion||2.61||$191.69 million||$0.57||115.00|
C.R. Bard has higher revenue and earnings than LivaNova PLC. C.R. Bard is trading at a lower price-to-earnings ratio than LivaNova PLC, indicating that it is currently the more affordable of the two stocks.
C.R. Bard beats LivaNova PLC on 12 of the 17 factors compared between the two stocks.
About C.R. Bard
C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.